The companies will initially contribute equally to funding the collaboration and will share in future proceeds from drugs developed within the partnership.
The deal follows the release of a report that, among other things, urged support for genomics and other life sciences in the UK.
The alliance's first aim is the identification, development, and validation of biomarkers of cancer and treatment response.
The firms will have exclusive access for a limited time to the data from the first 50,000 individuals with samples in the biobank to be sequenced.
The study seeks to identify biomarkers that can help personalize treatment for patients by identifying signs of rapid decline in kidney function.
GlaxoSmithKline and Verily Life Sciences form Galvani Bioelectronics.
Drug developers and genetic testing firms are contemplating how best to share variant classification data while protecting their commercial interests.
Five people have been indicted for stealing trade secrets from GlaxoSmithKline, the Wall Street Journal reports.
Therapies aimed at drug targets that have been linked genetically to disease fare better through the drug development pipeline, researchers from GSK and elsewhere found.
The institute will develop new technologies and approaches to decode how genes are controlled and how a cell's "operating system" functions.
CBS This Morning highlights recent Medicare fraud involving offers of genetic testing.
Researchers find that many cancer drugs in development don't work quite how their developers thought they did, as Discover's D-brief blog reports.
Mariya Gabriel, a Bulgarian politician, is to be the next European Union research commissioner, according to Science.
In Science this week: a survey indicates that US adults are more likely to support the agricultural use of gene drives if they target non-native species and if they are limited, and more.